Seminars in dialysis
-
Seminars in dialysis · May 2012
Editorial Case ReportsThe new label for erythropoiesis stimulating agents: the FDA'S sentence.
On June 24, 2011, the U. S. ⋯ We believe that the new label language may deprive patients of the full benefits of erythropoiesis-stimulating agent treatment and impair the opportunity to individualize treatment through shared decision making. Diminished discovery and innovation in the treatment of one of the most common and important complications of kidney disease may also be an unintended consequence of the label change.